X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
electricity (103) 103
basic electric elements (90) 90
humans (85) 85
devices using stimulated emission (79) 79
electric solid state devices not otherwise provided for (72) 72
semiconductor devices (72) 72
oncology (41) 41
performing operations (36) 36
transporting (36) 36
female (34) 34
male (31) 31
animals (22) 22
human necessities (22) 22
index medicus (22) 22
adult (20) 20
dose-response relationship, drug (20) 20
drug synergism (20) 20
middle aged (20) 20
hygiene (19) 19
manufacture or treatment of nanostructures (19) 19
measurement or analysis of nanostructures (19) 19
medical or veterinary science (19) 19
nanotechnology (19) 19
preparations for medical, dental, or toilet purposes (19) 19
specific uses or applications of nanostructures (19) 19
cancer (18) 18
aged (17) 17
hematology (16) 16
pharmacology & pharmacy (15) 15
physics (15) 15
apoptosis (14) 14
tumor cells, cultured (14) 14
cisplatin (13) 13
isobologram (13) 13
anticancer agents (12) 12
antineoplastic combined chemotherapy protocols - pharmacology (12) 12
cell line, tumor (12) 12
chemotherapy (12) 12
leukemia (12) 12
specific therapeutic activity of chemical compounds ormedicinal preparations (12) 12
cell division - drug effects (11) 11
combination (11) 11
drug administration schedule (11) 11
lymphoblastic-leukemia cells (11) 11
paclitaxel (11) 11
time factors (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
apoptosis - drug effects (9) 9
drug combination (9) 9
expression (9) 9
measuring (9) 9
mice (9) 9
testing (9) 9
acute myeloid-leukemia (8) 8
analysis (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
cell biology (8) 8
cells (8) 8
drug interactions (8) 8
electric communication technique (8) 8
k562 cells (8) 8
land vehicles for travelling otherwise than on rails (8) 8
lung neoplasms - drug therapy (8) 8
motor vehicles (8) 8
paclitaxel - administration & dosage (8) 8
trailers (8) 8
aged, 80 and over (7) 7
benzamides (7) 7
cell line (7) 7
drug screening assays, antitumor (7) 7
imatinib mesylate (7) 7
preparing clay (7) 7
producing mixtures containing clay or cementitious material,e.g. plaster (7) 7
stem cells (7) 7
trial (7) 7
tumor cells, cultured - drug effects (7) 7
vincristine - administration & dosage (7) 7
working cement, clay, or stone (7) 7
antineoplastic agents - pharmacology (6) 6
antineoplastic agents, phytogenic - administration & dosage (6) 6
biochemistry & molecular biology (6) 6
culture (6) 6
depsipeptides - pharmacology (6) 6
enzyme inhibitors - pharmacology (6) 6
irinotecan (6) 6
medicine (6) 6
neurosciences (6) 6
phase-ii (6) 6
phosphorylation (6) 6
piperazines - pharmacology (6) 6
pyrimidines - pharmacology (6) 6
survival rate (6) 6
up-regulation (6) 6
antibiotics, antineoplastic - pharmacology (5) 5
biology (5) 5
calculating (5) 5
camptothecin - analogs & derivatives (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
care and treatment (5) 5
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (316) 316
Japanese (20) 20
French (14) 14
German (13) 13
Chinese (6) 6
Danish (1) 1
Greek (1) 1
Portuguese (1) 1
Slovenian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 02/2014, Volume 9, Issue 2, p. e89707
Journal Article
International Journal of Hematology, ISSN 0925-5710, 4/2019, Volume 109, Issue 4, pp. 418 - 425
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2013, Volume 8, Issue 6, p. e66378
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by a block in differentiation and uncontrolled proliferation. FLT3 is a commonly mutated... 
CARCINOMA-CELLS | INTERNAL TANDEM DUPLICATION | BREAST-CANCER CELLS | HSP90 MOLECULAR CHAPERONE | TYROSINE KINASE DOMAIN | MULTIDISCIPLINARY SCIENCES | RECEPTOR | ACUTE MYELOID-LEUKEMIA | MUTATIONS | LINES | GALLATE | Phosphorylation | Gene Expression - drug effects | Humans | Infant | Male | Staurosporine - analogs & derivatives | Cell Line, Tumor - drug effects | fms-Like Tyrosine Kinase 3 - genetics | STAT5 Transcription Factor - metabolism | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Catechin - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Gene Expression Regulation, Leukemic - drug effects | Down-Regulation - drug effects | fms-Like Tyrosine Kinase 3 - metabolism | Drug Synergism | Point Mutation | HSP90 Heat-Shock Proteins - metabolism | Catechin - analogs & derivatives | Cell Proliferation - drug effects | Mutagenesis, Insertional | Protein Processing, Post-Translational | Staurosporine - pharmacology | Drug Screening Assays, Antitumor | Leukemia, Myeloid, Acute - genetics | Mitogen-Activated Protein Kinases - metabolism | Catechin | Gene mutations | Medicine, Botanic | Electrocardiogram | Electrocardiography | Medicine, Herbal | Green tea | Cell proliferation | EKG | Medical research | Myeloid leukemia | Leukemia | Epigallocatechin-3-gallate | Clinical trials | MAP kinase | AKT protein | Stat5 protein | Insulin-like growth factors | Kinases | Epicatechin | Catechins | Tea | Reagents | Cell lines | Polyphenols | Mutation | Inhibition | Acute myeloid leukemia
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2014, Volume 9, Issue 3, p. e90675
Bendamustine has shown considerable clinical activity against indolent lymphoid malignancies as a single agent or in combination with rituximab, but... 
IN-VITRO | REFRACTORY MULTIPLE-MYELOMA | MANTLE CELL LYMPHOMA | MULTIDISCIPLINARY SCIENCES | PLUS RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | OPEN-LABEL | PHASE-II MULTICENTER | INDOLENT B-CELL | PREVIOUSLY UNTREATED PATIENTS | Cyclophosphamide - administration & dosage | Cyclophosphamide - analogs & derivatives | Cell Proliferation | Lymphoma, Large B-Cell, Diffuse - pathology | Antineoplastic Combined Chemotherapy Protocols - chemistry | Humans | Lymphoma, Mantle-Cell - pathology | Cell Line, Tumor - drug effects | Antineoplastic Agents, Alkylating - administration & dosage | Cytarabine - administration & dosage | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Drug Synergism | Rituximab - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Multiple Myeloma - pathology | Cell Cycle | Inhibitory Concentration 50 | Bendamustine Hydrochloride - chemistry | Lymphoma - pathology | DNA Damage | Antineoplastic Agents, Alkylating - chemistry | Drug Screening Assays, Antitumor | Alkaloids | Care and treatment | Cyclophosphamide | Pyrimidines | Cytarabine | RNA | Analysis | DNA damage | DNA | Non-Hodgkin's lymphomas | DNA repair | Cancer | Drugs | Gemcitabine | Laboratories | Leukemia | Multiple myeloma | mRNA | Synergism | Cancer therapies | Alkylation | Chlorambucil | Synergistic effects | Metabolites | Melphalan | Cell cycle | Cytosine | Deoxyribonucleic acid--DNA | Cytosine arabinoside | Hematology | Alkylating agents | Rituximab | Gene expression | Lymphoma | Medicine | Studies | Chemotherapy | Fludarabine | Lymphocytes B | Cell lines | Mantle cell lymphoma | Reagents | Stem cells | Lymphomas | Tumors | Apoptosis | Pharmaceuticals | 5-aza-2'-deoxycytidine | B-cell lymphoma | Deoxyribonucleic acid
Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 2016, Volume 372, pp. 403 - 407
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 06/2008, Volume 128, Issue 6, pp. 1506 - 1516
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2013, Volume 8, Issue 4, p. e60649
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 10/2002, Volume 277, Issue 42, pp. 39760 - 39768
Journal Article
Blood, ISSN 0006-4971, 07/2010, Volume 116, Issue 3, pp. 406 - 417
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 12/2012, Volume 429, Issue 1-2, pp. 87 - 92
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2003, Volume 51, Issue 5, pp. 403 - 406
Purpose. Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a β-glucuronidase inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We... 
Non-small-cell lung cancer Irinotecan Diarrhea Kampo medicine Hangeshashin-to | Diarrhea | Non-small-cell lung cancer | Irinotecan | Hangeshashin-to | Kampo medicine | irinotecan | CPT-11 | PHASE-II | diarrhea | TRIAL